2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

908. Outcomes Research: Myeloid Malignancies: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Transplantation, Non-Biological Therapies, Anticoagulant Drugs, Chemotherapy, Pharmacology, Women’s Health, Adverse Events, Artificial Intelligence (AI), Machine Learning, Natural Language Processing, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Value, Diseases, Bleeding and Clotting, Thromboembolism, Bone Marrow Failure Syndromes, Genetic Disorders, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, MDS, MPN, CML, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

2836 Endothelial activation and stress index (EASIX) score explored as a potential early indicator of capillary leak syndrome (CLS) during tagraxofusp (TAG) treatment for patients (pts) with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Subgroup analysis of a pivotal trial

Shai Shimony, MD, MPH, Naveen Pemmaraju, MD2, Marina Konopleva, MD, PhD3, Kendra L. Sweet, MD, MS4, Anthony Selwyn Stein, MD5, David A. Rizzieri, MD6, Eunice Sue Wang, MD7, Sumithira Vasu, MBBS., MD8, Raajit K. Rampal, MD, PhD9, Ami B. Patel, MD10, Alessandra Tosolini, MD, PhD11, Mike Zuurman, MD, PhD12, Andrew A. Lane, MD, PhD13
1 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
2 The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States
3 Albert Einstein College of Medicine/Montefiore Cancer Center, Bronx, New York, United States
4 Moffitt Cancer Center, Tampa, Florida, United States
5 City of Hope, Duarte, California, United States
6 Novant Health Cancer Institute, Charlotte, North Carolina, United States
7 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
8 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
9 Memorial Sloan Kettering Cancer Center, New York, New York, United States
10 Huntsman Cancer Institute, Salt Lake City, Utah, United States
11 Menarini Group, New York, New York, United States
12 Menarini Group, Machelen, Belgium
13 Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Introduction
BPDCN is an aggressive orphan hematologic malignancy characterized by ubiquitous high expression of CD123 on tumor cells. TAG, a first-in-class CD123-targeted therapy, is approved to treat BPDCN based on a pivotal multicenter phase 2 trial (NCT02113982; Pemmaraju NEJM 2019). Real-world data and pivotal trial subanalyses highlight TAG’s efficacy and safety in BPDCN, regardless of fitness level and pt/disease characteristics, enabling bridge to hematopoetic stem cell transplant. TAG has a well-characterized and manageable safety profile, no cumulative toxicity, no myelosuppression; the majority of pts have rapid restoration of normal hematopoiesis during treatment. CLS, observed with other CD123 therapies, was reported in 21% of TAG-treated pts in the pivotal trial; most events (67%) were grade (gr) 1-2, limited to first cycle (94%) and did not recur (Pemmaraju JCO 2022). As CLS may be life-threatening in some cases, early management is critical. The EASIX score is a marker of endothelial damage and associated with prognostic outcomes in several settings, including post-transplant and after CAR T-cell therapy in leukemia (Goel BMT 2025; Nawas Blood Adv 2022). Given that CLS involves endothelial injury, we sought to evaluate the EASIX score as an early marker of CLS in BPDCN pts treated with TAG.

Methods
We conducted a post hoc descriptive analysis of pts with BPDCN who received 12 µg/kg IV TAG monotherapy on days 1-5 of a 21-day (D) cycle (C) in the pivotal trial. The EASIX score (lactate dehydrogenase [LDH; U/L] × creatinine [mg/dL] / platelets [plt; 109/L]) was calculated in C1 on D1-5, 8, and 15. We evaluated the absolute and dynamic EASIX values (deltaEASIX, median percentage change in EASIX score) between pts with CLS presence (CLS-present) or absence (CLS-absent). Driver components of EASIX score (LDH, plt count) were also evaluated.

Results
Of 86 pts, 68 (79%) were CLS-absent; 18 (21%) were CLS-present. The median age was 68.5 years (range, 22-87) in CLS-absent pts and 72 years (range 55-79) in CLS-present pts. Male gender (82%, 78%) and baseline (bl) ECOG performance status 0-1 (97%, 100%) were numerically similar. Twelve pts had gr 1-2 CLS; 6 had gr 3+; median onset for any gr CLS was 6 days from treatment start (quartile [Q]1-Q3, 4-8) with a 6-day (range, 3-69) time to resolution.

The median (Q1-Q3) bl EASIX (mEASIX) score was 2.4 (1.3-5.7) in CLS-absent pts and 2.1 (1.2-2.5) in CLS-present pts. The mEASIX score was 2.4 (1.7-2.5) in pts who developed gr 1-2 CLS vs 1.1 (0.6-5.6) in pts who developed gr 3+ CLS. Across all groups, mEASIX peaked at C1D8 and decreased by C1D15.

During C1 TAG infusion (D1-5), in pts with gr 1-2 CLS, mEASIX more than doubled between D2 and D4 (2.0 C1D2 to 4.1 on C1D4); in CLS-absent pts, C1D2 mEASIX was 3.0 and C1D4, 5.0. Notably, pts with gr 3+ CLS had a more rapid doubling, occurring after only 1 infusion day (rising from 1.3 C1D2 to 3.3 on C1D3).

When evaluating the deltaEASIX during C1, CLS-present pts showed a higher median percentage increase than CLS-absent pts. In CLS-absent pts, deltaEASIX increased during infusion days (maximum, 70.5% on C1D5) and peaked at 120.7% postinfusion on C1D8. In contrast, in CLS-present pts, deltaEASIX had a higher magnitude and rate of increase, to 186.1% by C1D4, 229.7% by C1D5, and peaked at 1101.4% postinfusion on C1D8. Of note, a deltaEASIX score >200% within the first 5 infusion days was only observed in CLS-present pts.

When evaluating EASIX score individual components, a marked decrease in plts (bl, 107; C1D3, 88; C1D5, 72) and increase in LDH (bl, 197; C1D3, 261; C1D5, 550) were observed during the first 5 TAG dosing days in CLS-present pts. In CLS-absent pts, respective plt decline was 112, 102, 92 and LDH increase was 264, 360, 494.

Conclusions
Findings from this exploratory analysis suggest that EASIX may serve as an early indicator of CLS during TAG treatment to trigger early intervention and further enhance manageability. In particular, the deltaEASIX score doubled within the first 5 infusion days for pts with CLS (229.7%) and did not double for CLS-absent pts (70.5%). The EASIX increase was driven by an early decline in platelet counts and a rise in LDH. The decrease in platelets may reflect increased vascular leakage requiring vascular repair, whereas elevated LDH is consistent with tumor cell destruction and/or endothelial damage. Further validation is needed to confirm these results.

Shai Shimony, MD, MPH: Syndax - Research Funding